Business Context and Reporting Period
This Form 6-K filing by BioBlast Pharma Ltd. (also referenced as Enlivex Ltd. in metadata) covers the month of August 2017. The registrant is a foreign private issuer based in Tel Aviv, Israel, filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a notice of a corporate governance event rather than a financial report.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The primary content is the announcement of an Extraordinary General Meeting of Shareholders scheduled for September 18, 2017.
Guidance, Outlook, and Corporate Actions
- Shareholder Meeting: An Extraordinary General Meeting is scheduled for Monday, September 18, 2017.
- Record Date: Only shareholders of record holding Ordinary Shares (nominal value NIS 0.01) at the close of trading on the Nasdaq Capital Market on August 21, 2017, are entitled to vote.
- Regulatory Integration: The Notice of Meeting and Proxy Statement are incorporated by reference into the registrant's Form F-3 (File No. 333-206032) and Form S-8 (File Nos. 333-203114 and 333-210459) registration statements.
Investor Verification Checklist
- Verify the specific agenda items for the Extraordinary General Meeting by reviewing the attached Exhibit 99.1 (Proxy Statement).
- Confirm share ownership status as of the August 21, 2017, record date to ensure voting eligibility.
- Review the referenced Form F-3 and Form S-8 filings for details on how this meeting impacts pending registration statements.